Search

Your search keyword '"Salama, Mohamed E."' showing total 618 results
Start Over Author "Salama, Mohamed E."
618 results on '"Salama, Mohamed E."'

3. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Author

Dunbar, Andrew J., Kim, Dongjoo, Lu, Min, Farina, Mirko, Bowman, Robert L., Yang, Julie L., Park, Young, Karzai, Abdul, Xiao, Wenbin, Zaroogian, Zach, O’Connor, Kavi, Mowla, Shoron, Gobbo, Francesca, Verachi, Paola, Martelli, Fabrizio, Sarli, Giuseppe, Xia, Lijuan, Elmansy, Nada, Kleppe, Maria, Chen, Zhuo, Xiao, Yang, McGovern, Erin, Snyder, Jenna, Krishnan, Aishwarya, Hill, Corrine, Cordner, Keith, Zouak, Anouar, Salama, Mohamed E., Yohai, Jayden, Tucker, Eric, Chen, Jonathan, Zhou, Jing, McConnell, Timothy, Migliaccio, Anna R., Koche, Richard, Rampal, Raajit, Fan, Rong, Levine, Ross L., and Hoffman, Ronald

Published
2023
Full Text
View/download PDF

4. The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment

Author

Mollaoglu, Gurkan, Jones, Alex, Wait, Sarah J, Mukhopadhyay, Anandaroop, Jeong, Sangmin, Arya, Rahul, Camolotto, Soledad A, Mosbruger, Timothy L, Stubben, Chris J, Conley, Christopher J, Bhutkar, Arjun, Vahrenkamp, Jeffery M, Berrett, Kristofer C, Cessna, Melissa H, Lane, Thomas E, Witt, Benjamin L, Salama, Mohamed E, Gertz, Jason, Jones, Kevin B, Snyder, Eric L, and Oliver, Trudy G

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Genetics, Lung, Lung Cancer, Cancer, 2.1 Biological and endogenous factors, Aetiology, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Cell Line, Tumor, Cell Lineage, Cells, Cultured, Disease Models, Animal, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, HEK293 Cells, Humans, Lung Neoplasms, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Neutrophils, SOXB1 Transcription Factors, Thyroid Nuclear Factor 1, Tumor Microenvironment, CXCL5, NKX2-1, SOX2, adenocarcinoma, lung cancer, mouse models, squamous, transdifferentiation, tumor immune microenvironment, tumor-associated neutrophils
Abstract

The major types of non-small-cell lung cancer (NSCLC)-squamous cell carcinoma and adenocarcinoma-have distinct immune microenvironments. We developed a genetic model of squamous NSCLC on the basis of overexpression of the transcription factor Sox2, which specifies lung basal cell fate, and loss of the tumor suppressor Lkb1 (SL mice). SL tumors recapitulated gene-expression and immune-infiltrate features of human squamous NSCLC; such features included enrichment of tumor-associated neutrophils (TANs) and decreased expression of NKX2-1, a transcriptional regulator that specifies alveolar cell fate. In Kras-driven adenocarcinomas, mis-expression of Sox2 or loss of Nkx2-1 led to TAN recruitment. TAN recruitment involved SOX2-mediated production of the chemokine CXCL5. Deletion of Nkx2-1 in SL mice (SNL) revealed that NKX2-1 suppresses SOX2-driven squamous tumorigenesis by repressing adeno-to-squamous transdifferentiation. Depletion of TANs in SNL mice reduced squamous tumors, suggesting that TANs foster squamous cell fate. Thus, lineage-defining transcription factors determine the tumor immune microenvironment, which in turn might impact the nature of the tumor.

Published
2018

5. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study

Author

Byeon, Seul Kee, Madugundu, Anil K, Garapati, Kishore, Ramarajan, Madan Gopal, Saraswat, Mayank, Kumar-M, Praveen, Hughes, Travis, Shah, Rameen, Patnaik, Mrinal M, Chia, Nicholas, Ashrafzadeh-Kian, Susan, Yao, Joseph D, Pritt, Bobbi S, Cattaneo, Roberto, Salama, Mohamed E, Zenka, Roman M, Kipp, Benjamin R, Grebe, Stefan K G, Singh, Ravinder J, Sadighi Akha, Amir A, Algeciras-Schimnich, Alicia, Dasari, Surendra, Olson, Janet E, Walsh, Jesse R, Venkatakrishnan, A J, Jenkinson, Garrett, O'Horo, John C, Badley, Andrew D, and Pandey, Akhilesh

Published
2022
Full Text
View/download PDF

8. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

Author

Mascarenhas, John O., Rampal, Raajit K., Kosiorek, Heidi E., Bhave, Rupali, Hexner, Elizabeth, Wang, Eunice S., Gerds, Aaron, Abboud, Camille N., Kremyanskaya, Marina, Berenzon, Dimitry, Odenike, Olatoyosi, Farnoud, Noushin, Krishnan, Aishwarya, Weinberg, Rona Singer, McGovern, Erin, Salama, Mohamed E., Najfeld, Vesna, Medina-Martinez, Juan S., Arango Ossa, Juan E., Levine, Max F., Zhou, Yangyu, Sandy, Lonette, Heaney, Mark L., Levine, Ross L., Mesa, Ruben A., Dueck, Amylou C., and Hoffman, Ronald

Published
2020
Full Text
View/download PDF

9. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

Author

Mascarenhas, John, primary, Kremyanskaya, Marina, additional, Patriarca, Andrea, additional, Palandri, Francesca, additional, Devos, Timothy, additional, Passamonti, Francesco, additional, Rampal, Raajit K., additional, Mead, Adam J., additional, Hobbs, Gabriella, additional, Scandura, Joseph M., additional, Talpaz, Moshe, additional, Granacher, Nikki, additional, Somervaille, Tim C. P., additional, Hoffman, Ronald, additional, Wondergem, Marielle J., additional, Salama, Mohamed E., additional, Colak, Gozde, additional, Cui, Jike, additional, Kiladjian, Jean-Jacques, additional, Vannucchi, Alessandro M., additional, Verstovsek, Srdan, additional, Curto-García, Natalia, additional, Harrison, Claire, additional, and Gupta, Vikas, additional

Published
2023
Full Text
View/download PDF

10. Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists

Author

Bui, Marilyn M., Riben, Michael W., Allison, Kimberly H., Chlipala, Elizabeth, Colasacco, Carol, Kahn, Andrea G., Lacchetti, Christina, Madabhushi, Anant, Pantanowitz, Liron, Salama, Mohamed E., Stewart, Rachel L., Thomas, Nicole E., Tomaszewski, John E., and Hammond, M. Elizabeth

Subjects
United States. Food and Drug Administration, Quality control, Medical societies, Immunohistochemistry, Epidermal growth factors, Imaging systems -- Quality management, Breast cancer, Scientists, Technology, Imaging technology, Quality control, Health
Abstract

* Context.--Advancements in genomic, computing, and imaging technology have spurred new opportunities to use quantitative image analysis (QIA) for diagnostic testing. Objective.--To develop evidence-based recommendations to improve accuracy, precision, and reproducibility in the interpretation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) for breast cancer where QIA is used. Design.--The College of American Pathologists (CAP) convened a panel of pathologists, histotechnologists, and computer scientists with expertise in image analysis, immunohistochemistry, quality management, and breast pathology to develop recommendations for QIA of HER2 IHC in breast cancer. A systematic review of the literature was conducted to address 5 key questions. Final recommendations were derived from strength of evidence, open comment feedback, expert panel consensus, and advisory panel review. Results.--Eleven recommendations were drafted: 7 based on CAP laboratory accreditation requirements and 4 based on expert consensus opinions. A 3-week open comment period received 180 comments from more than 150 participants. Conclusions.--To improve accurate, precise, and reproducible interpretation of HER2 IHC results for breast cancer, QIA and procedures must be validated before implementation, followed by regular maintenance and ongoing evaluation of quality control and quality assurance. HER2 QIA performance, interpretation, and reporting should be supervised by pathologists with expertise in QIA. (Arch Pathol Lab Med. 2019;143:1180-1195; doi: 10.5858/arpa.2018-0378-CP), In the United States, breast cancer is the most common type of cancer in women and 1 in 8 women will develop breast cancer in her lifetime. (1) For breast [...]

Published
2019
Full Text
View/download PDF

12. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study

Author

Mascarenhas, John, Kremyanskaya, Marina, Patriarca, Andrea, Harrison, Claire, Bose, Prithviraj, Rampal, Raajit K, Palandri, Francesca, Devos, Timothy, Passamonti, Francesco, Hobbs, Gabriela, Talpaz, Moshe, Vannucchi, Alessandro, Kiladjian, Jean-Jacques, Verstovsek, Srdan, Hoffman, Ron, Salama, Mohamed E, Chen, Dong, Taverna, Pietro, Chang, Alex, Colak, Gozde, Klein, Sandra, and Gupta, Vikas

Published
2022
Full Text
View/download PDF

13. Supplementary Figure S5 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis

Author

Mascarenhas, John, primary, Migliaccio, Anna Rita, primary, Kosiorek, Heidi, primary, Bhave, Rupali, primary, Palmer, Jeanne, primary, Kuykendall, Andrew, primary, Mesa, Ruben, primary, Rampal, Raajit K., primary, Gerds, Aaron T., primary, Yacoub, Abdulraheem, primary, Pettit, Kristen, primary, Talpaz, Moshe, primary, Komrokji, Rami, primary, Kremyanskaya, Marina, primary, Gonzalez, Agapito, primary, Fabris, Frank, primary, Johnson, Kathryn, primary, Dougherty, Mikaela, primary, McGovern, Erin, primary, Arango Ossa, Juan, primary, Domenico, Dylan, primary, Farnoud, Noushin, primary, Weinberg, Rona Singer, primary, Kong, Amy, primary, Najfeld, Vesna, primary, Vannucchi, Alessandro Maria, primary, Arciprete, Francesca, primary, Zingariello, Maria, primary, Falchi, Mario, primary, Salama, Mohamed E., primary, Mead-Harvey, Carolyn, primary, Dueck, Amylou, primary, Varricchio, Lilian, primary, and Hoffman, Ronald, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table S3 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis

Author

Mascarenhas, John, primary, Migliaccio, Anna Rita, primary, Kosiorek, Heidi, primary, Bhave, Rupali, primary, Palmer, Jeanne, primary, Kuykendall, Andrew, primary, Mesa, Ruben, primary, Rampal, Raajit K., primary, Gerds, Aaron T., primary, Yacoub, Abdulraheem, primary, Pettit, Kristen, primary, Talpaz, Moshe, primary, Komrokji, Rami, primary, Kremyanskaya, Marina, primary, Gonzalez, Agapito, primary, Fabris, Frank, primary, Johnson, Kathryn, primary, Dougherty, Mikaela, primary, McGovern, Erin, primary, Arango Ossa, Juan, primary, Domenico, Dylan, primary, Farnoud, Noushin, primary, Weinberg, Rona Singer, primary, Kong, Amy, primary, Najfeld, Vesna, primary, Vannucchi, Alessandro Maria, primary, Arciprete, Francesca, primary, Zingariello, Maria, primary, Falchi, Mario, primary, Salama, Mohamed E., primary, Mead-Harvey, Carolyn, primary, Dueck, Amylou, primary, Varricchio, Lilian, primary, and Hoffman, Ronald, primary

Published
2023
Full Text
View/download PDF

15. Data from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis

Author

Mascarenhas, John, primary, Migliaccio, Anna Rita, primary, Kosiorek, Heidi, primary, Bhave, Rupali, primary, Palmer, Jeanne, primary, Kuykendall, Andrew, primary, Mesa, Ruben, primary, Rampal, Raajit K., primary, Gerds, Aaron T., primary, Yacoub, Abdulraheem, primary, Pettit, Kristen, primary, Talpaz, Moshe, primary, Komrokji, Rami, primary, Kremyanskaya, Marina, primary, Gonzalez, Agapito, primary, Fabris, Frank, primary, Johnson, Kathryn, primary, Dougherty, Mikaela, primary, McGovern, Erin, primary, Arango Ossa, Juan, primary, Domenico, Dylan, primary, Farnoud, Noushin, primary, Weinberg, Rona Singer, primary, Kong, Amy, primary, Najfeld, Vesna, primary, Vannucchi, Alessandro Maria, primary, Arciprete, Francesca, primary, Zingariello, Maria, primary, Falchi, Mario, primary, Salama, Mohamed E., primary, Mead-Harvey, Carolyn, primary, Dueck, Amylou, primary, Varricchio, Lilian, primary, and Hoffman, Ronald, primary

Published
2023
Full Text
View/download PDF

16. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis

Author

Mascarenhas, John, primary, Migliaccio, Anna Rita, additional, Kosiorek, Heidi, additional, Bhave, Rupali, additional, Palmer, Jeanne, additional, Kuykendall, Andrew, additional, Mesa, Ruben, additional, Rampal, Raajit K., additional, Gerds, Aaron T., additional, Yacoub, Abdulraheem, additional, Pettit, Kristen, additional, Talpaz, Moshe, additional, Komrokji, Rami, additional, Kremyanskaya, Marina, additional, Gonzalez, Agapito, additional, Fabris, Frank, additional, Johnson, Kathryn, additional, Dougherty, Mikaela, additional, McGovern, Erin, additional, Arango Ossa, Juan, additional, Domenico, Dylan, additional, Farnoud, Noushin, additional, Weinberg, Rona Singer, additional, Kong, Amy, additional, Najfeld, Vesna, additional, Vannucchi, Alessandro Maria, additional, Arciprete, Francesca, additional, Zingariello, Maria, additional, Falchi, Mario, additional, Salama, Mohamed E., additional, Mead-Harvey, Carolyn, additional, Dueck, Amylou, additional, Varricchio, Lilian, additional, and Hoffman, Ronald, additional

Published
2023
Full Text
View/download PDF

17. Predictive Markers Require Thorough Analytic Validation

Author

Troxell, Megan L., Fulton, Regan S., Swanson, Paul E., Bellizzi, Andrew M., Fitzgibbons, Patrick L., Ambaye, Abiy B., Haas, Thomas S., Goldsmith, Jeffrey D., Loykasek, Patti A., Miller, Dylan V., O'Malley, Dennis, Qiu, Jingxin, Salama, Mohamed E., Schaberg, Kurt B., Schwartz, Robert A., Shia, Jinru, Summers, Thomas A., Jr., and Wu, Yaping

Subjects
United States. Food and Drug Administration, Immunohistochemistry, Non-small cell lung cancer, Small cell lung cancer, Health
Abstract

To the Editor. -- The recent editorial by Erik Thunnissen, 'How to Validate Predictive Immunohistochemistry Testing in Pathology? A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in [...]

Published
2019

18. Molecular Fingerprinting of Anatomically and Temporally Distinct B-Cell Lymphoma Samples by Next-Generation Sequencing to Establish Clonal Relatedness

Author

Matynia, Anna P., Li, K. David, Szankasi, Philippe, Schumacher, Jonathan, Liew, Michael, Salama, Mohamed E., and Kelley, Todd W.

Subjects
Nucleotide sequencing -- Usage, Lymphomas -- Genetic aspects -- Diagnosis -- Research, DNA sequencing -- Usage, Health
Abstract

* Context.--B-cell lymphomas exhibit balanced translocations that involve immunoglobulin loci and result from aberrant V(D)J recombination, class switch recombination, or somatic hypermutation. Although most of the breakpoints in the immunoglobulin loci occur in defined regions, those in the partner genes vary; therefore, it is unlikely that 2 independent clones would share identical breakpoints in both partners. Establishing whether a new lesion in a patient with history of lymphoma represents recurrence or a new process can be relevant. Polymerase chain reaction (PCR)-based clonality assays used in this setting rely only on evaluating the length of a given rearrangement. In contrast, next-generation sequencing (NGS) provides the exact translocation breakpoint at single-base resolution. Objective.--To determine if translocation breakpoint coordinates can serve as a molecular fingerprint unique to a distinct clonal population. Design.--Thirty-eight follicular lymphoma/diffuse large B-cell lymphoma samples collected from different anatomic sites and/or at different time points from 18 patients were analyzed by NGS. For comparison, PCR-based B-cell clonality and fluorescence in situ hybridization studies were performed on a subset of cases. Results.--IGH-BCL2 rearrangements were detected in all samples. The breakpoint coordinates on derivative chromosome(s) were identical in all samples from a given patient, but distinct between samples derived from different patients. Additionally, 5 patients carried a second rearrangement also with conserved breakpoint coordinates in the follow-up sample(s). Conclusions.--Breakpoint coordinates in the immunoglobulin and partner genes can be used to establish clonal relatedness of anatomically/temporally distinct lesions. Additionally, an NGS-based approach has the potential to detect secondary translocations that may have prognostic and therapeutic significance. doi: 10.5858/arpa.2017-0497-OA), B-cell neoplasms, such as mantle cell lymphoma, follicular lymphoma (FL), and Burkitt lymphoma, have characteristic genetic abnormalities that are important in determining their biologic features, and their detection may aid [...]

Published
2019
Full Text
View/download PDF

19. US Food and Drug Administration Approval of Whole Slide Imaging for Primary Diagnosis: A Key Milestone Is Reached and New Questions Are Raised

Author

Evans, Andrew J., Bauer, Thomas W., Bui, Marilyn M., Cornish, Toby C., Duncan, Helena, Glassy, Eric F., Hipp, Jason, McGee, Robert S., Murphy, Doug, Myers, Charles, O'Neill, Dennis G., Parwani, Anil V., Rampy, B. Alan, Salama, Mohamed E., and Pantanowitz, Liron

Subjects
Diagnostic imaging -- Evaluation, Pathological histology -- Innovations, Medical societies, Universities and colleges, Technology, Health
Abstract

* April 12, 2017 marked a significant day in the evolution of digital pathology in the United States, when the US Food and Drug Administration announced its approval of the Philips IntelliSite Pathology Solution for primary diagnosis in surgical pathology. Although this event is expected to facilitate more widespread adoption of whole slide imaging for clinical applications in the United States, it also raises a number of questions as to the means by which pathologists might choose to incorporate this technology into their clinical practice. This article from the College of American Pathologists Digital Pathology Committee reviews frequently asked questions on this topic and provides answers based on currently available information.(Arch Pathol Lab Med. 2018;142:1383-1387; doi: 10.5858/arpa.2017-0496-CP), On April 12, 2017, the US Food and Drug Administration (FDA) announced the approval of the first whole slide imaging (WSI) system for primary diagnosis in surgical pathology. (1) This [...]

Published
2018
Full Text
View/download PDF

26. Supplementary Table 1 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

Author

Yan, Dongqing, primary, Pomicter, Anthony D., primary, Tantravahi, Srinivas, primary, Mason, Clinton C., primary, Senina, Anna V., primary, Ahmann, Jonathan M., primary, Wang, Qiang, primary, Than, Hein, primary, Patel, Ami B., primary, Heaton, William L., primary, Eiring, Anna M., primary, Clair, Phillip M., primary, Gantz, Kevin C., primary, Redwine, Hannah M., primary, Swierczek, Sabina I., primary, Halverson, Brayden J., primary, Baloglu, Erkan, primary, Shacham, Sharon, primary, Khorashad, Jamshid S., primary, Kelley, Todd W., primary, Salama, Mohamed E., primary, Miles, Rodney R., primary, Boucher, Kenneth M., primary, Prchal, Josef T., primary, O'Hare, Thomas, primary, and Deininger, Michael W., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 6 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

Author

Yan, Dongqing, primary, Pomicter, Anthony D., primary, Tantravahi, Srinivas, primary, Mason, Clinton C., primary, Senina, Anna V., primary, Ahmann, Jonathan M., primary, Wang, Qiang, primary, Than, Hein, primary, Patel, Ami B., primary, Heaton, William L., primary, Eiring, Anna M., primary, Clair, Phillip M., primary, Gantz, Kevin C., primary, Redwine, Hannah M., primary, Swierczek, Sabina I., primary, Halverson, Brayden J., primary, Baloglu, Erkan, primary, Shacham, Sharon, primary, Khorashad, Jamshid S., primary, Kelley, Todd W., primary, Salama, Mohamed E., primary, Miles, Rodney R., primary, Boucher, Kenneth M., primary, Prchal, Josef T., primary, O'Hare, Thomas, primary, and Deininger, Michael W., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 2 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

Author

Yan, Dongqing, primary, Pomicter, Anthony D., primary, Tantravahi, Srinivas, primary, Mason, Clinton C., primary, Senina, Anna V., primary, Ahmann, Jonathan M., primary, Wang, Qiang, primary, Than, Hein, primary, Patel, Ami B., primary, Heaton, William L., primary, Eiring, Anna M., primary, Clair, Phillip M., primary, Gantz, Kevin C., primary, Redwine, Hannah M., primary, Swierczek, Sabina I., primary, Halverson, Brayden J., primary, Baloglu, Erkan, primary, Shacham, Sharon, primary, Khorashad, Jamshid S., primary, Kelley, Todd W., primary, Salama, Mohamed E., primary, Miles, Rodney R., primary, Boucher, Kenneth M., primary, Prchal, Josef T., primary, O'Hare, Thomas, primary, and Deininger, Michael W., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 3-8 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

Author

Yan, Dongqing, primary, Pomicter, Anthony D., primary, Tantravahi, Srinivas, primary, Mason, Clinton C., primary, Senina, Anna V., primary, Ahmann, Jonathan M., primary, Wang, Qiang, primary, Than, Hein, primary, Patel, Ami B., primary, Heaton, William L., primary, Eiring, Anna M., primary, Clair, Phillip M., primary, Gantz, Kevin C., primary, Redwine, Hannah M., primary, Swierczek, Sabina I., primary, Halverson, Brayden J., primary, Baloglu, Erkan, primary, Shacham, Sharon, primary, Khorashad, Jamshid S., primary, Kelley, Todd W., primary, Salama, Mohamed E., primary, Miles, Rodney R., primary, Boucher, Kenneth M., primary, Prchal, Josef T., primary, O'Hare, Thomas, primary, and Deininger, Michael W., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 3 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis

Author

Yan, Dongqing, primary, Pomicter, Anthony D., primary, Tantravahi, Srinivas, primary, Mason, Clinton C., primary, Senina, Anna V., primary, Ahmann, Jonathan M., primary, Wang, Qiang, primary, Than, Hein, primary, Patel, Ami B., primary, Heaton, William L., primary, Eiring, Anna M., primary, Clair, Phillip M., primary, Gantz, Kevin C., primary, Redwine, Hannah M., primary, Swierczek, Sabina I., primary, Halverson, Brayden J., primary, Baloglu, Erkan, primary, Shacham, Sharon, primary, Khorashad, Jamshid S., primary, Kelley, Todd W., primary, Salama, Mohamed E., primary, Miles, Rodney R., primary, Boucher, Kenneth M., primary, Prchal, Josef T., primary, O'Hare, Thomas, primary, and Deininger, Michael W., primary

Published
2023
Full Text
View/download PDF

31. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis

Author

Dunbar, Andrew, primary, Kim, Dongjoo, additional, Lu, Min, additional, Farina, Mirko, additional, Bowman, Robert L., additional, Yang, Julie L., additional, Park, Young C., additional, Karzai, Abdul, additional, Xiao, Wenbin, additional, Zaroogian, Zach, additional, O'Connor, Kavi, additional, Mowla, Shoron, additional, Gobbo, Francesca, additional, Verachi, Paola, additional, Martelli, Fabrizio, additional, Sarli, Giuseppe, additional, Xia, Lijuan, additional, Elmansy, Nada, additional, Kleppe, Maria, additional, Chen, Zhuo, additional, Xiao, Yang, additional, McGovern, Erin M, additional, Snyder, Jenna, additional, Krishnan, Aishwarya, additional, Hill, Corinne E., additional, Cordner, Keith Bryan, additional, Zouak, Anouar, additional, Salama, Mohamed E., additional, Yohai, Jayden, additional, Tucker, Eric, additional, Chen, Jonathan J, additional, Zhou, Jing, additional, McConnell, Timothy S, additional, Migliaccio, Anna Rita, additional, Koche, Richard Patrick, additional, Rampal, Raajit K., additional, Fan, Rong, additional, Levine, Ross L, additional, and Hoffman, Ronald, additional

Published
2023
Full Text
View/download PDF

32. Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade

Author

Berbís, M. Alvaro, primary, McClintock, David S., additional, Bychkov, Andrey, additional, Van der Laak, Jeroen, additional, Pantanowitz, Liron, additional, Lennerz, Jochen K., additional, Cheng, Jerome Y., additional, Delahunt, Brett, additional, Egevad, Lars, additional, Eloy, Catarina, additional, Farris, Alton B., additional, Fraggetta, Filippo, additional, García del Moral, Raimundo, additional, Hartman, Douglas J., additional, Herrmann, Markus D., additional, Hollemans, Eva, additional, Iczkowski, Kenneth A., additional, Karsan, Aly, additional, Kriegsmann, Mark, additional, Salama, Mohamed E., additional, Sinard, John H., additional, Tuthill, J. Mark, additional, Williams, Bethany, additional, Casado-Sánchez, César, additional, Sánchez-Turrión, Víctor, additional, Luna, Antonio, additional, Aneiros-Fernández, José, additional, and Shen, Jeanne, additional

Published
2023
Full Text
View/download PDF

36. Dedication

Author

Hoffman, Ronald, primary, Benz, Edward J., additional, Silberstein, Leslie E., additional, Heslop, Helen E., additional, Weitz, Jeffrey I., additional, Anastasi, John, additional, Salama, Mohamed E., additional, and Abutalib, Syed Ali, additional

Published
2018
Full Text
View/download PDF

37. Contributors

Author

Abdel-Wahab, Omar, primary, Abrahm, Janet L., additional, Adams, Sharon, additional, Adewoye, Adeboye H., additional, Allen, Carl, additional, Ambinder, Richard F., additional, Anasetti, Claudio, additional, Anastasi, John, additional, Anderson, Julia A., additional, Antin, Joseph H., additional, Antony, Aśok C., additional, Araten, David J., additional, Armand, Philippe, additional, Armstrong, Gillian, additional, Armstrong, Scott A., additional, Arnold, Donald M., additional, Artz, Andrew S., additional, Awan, Farrukh T., additional, Baglin, Trevor P., additional, Benson, Don M., additional, Benz, Edward J., additional, Berliner, Nancy, additional, Bhagat, Govind, additional, Bhardwaj, Nina, additional, Bhatia, Ravi, additional, Bhatia, Smita, additional, Bhatt, Mihir D., additional, Bhatt, Vijaya Raj, additional, Bitan, Menachem, additional, Blinderman, Craig D., additional, Bollard, Catherine M., additional, Braun, Benjamin S., additional, Brenner, Malcolm K., additional, Brittenham, Gary M., additional, Brodsky, Robert A., additional, Brown, Myles, additional, Broxmeyer, Hal E., additional, Brummel-Ziedins, Kathleen, additional, Brunner, Andrew M., additional, Buadi, Francis K., additional, Burkhardt, Birgit, additional, Burns, Melissa, additional, Byrd, John C., additional, Caimi, Paolo F., additional, Caligiuri, Michael A., additional, Canavan, Michelle, additional, Cantor, Alan B., additional, Carcao, Manuel, additional, Carroll, Michael C., additional, Carty, Shannon A., additional, Castillo, Jorge J., additional, Chan, Anthony K.C., additional, Chapin, John, additional, Chiu, April, additional, Chute, John P., additional, Clark, David B., additional, Coates, Thomas D., additional, Cogle, Christopher R., additional, Connell, Nathan T., additional, Cooke, Elizabeth, additional, Cooley, Sarah, additional, Corradini, Paolo, additional, Creager, Mark A., additional, Creger, Richard J., additional, Cromwell, Caroline, additional, Crowther, Mark A., additional, Cushing, Melissa M., additional, Cutler, Corey, additional, Dang, Chi V., additional, Danial, Nika N., additional, Dave, Sandeep S., additional, DeCaprio, James A., additional, Dinauer, Mary C., additional, Dinner, Shira, additional, Diz-Küçükkaya, Reyhan, additional, Dodd, Roger Y., additional, Donato, Michele L., additional, Dorshkind, Kenneth, additional, Dotti, Gianpietro, additional, Dror, Yigal, additional, Dunleavy, Kieron, additional, Dvorak, Christopher C., additional, Ebert, Benjamin L., additional, Eck, Michael J., additional, Eikelboom, John W., additional, Epperla, Narendranath, additional, Ershler, William B., additional, Evans, William E., additional, Faderl, Stefan, additional, Ferrara, James L.M., additional, Filipovich, Alexandra Hult, additional, Fischer, Martin, additional, Fredenburgh, James C., additional, Friedman, Kenneth D., additional, Fuchs, Ephraim, additional, Fuller, Stephen J., additional, Gailani, David, additional, Galipeau, Jacques, additional, Gallagher, Patrick G., additional, Ganapathi, Karthik A., additional, Gardner, Lawrence B., additional, Gee, Adrian P., additional, Gerson, Stanton L., additional, Gertz, Morie A., additional, Giardina, Patricia J., additional, Gibson, Christopher J., additional, Golan, Karin, additional, Golub, Todd R., additional, Gonzales, Matthew J., additional, Gotlib, Jason, additional, Gottschalk, Stephen, additional, Grant, Marianne A., additional, Graubert, Timothy A., additional, Gregg, Xylina T., additional, Gribben, John G., additional, Gross, Dawn M., additional, Gruber, Tanja A., additional, Guitart, Joan, additional, Gurbuxani, Sandeep, additional, Gur-Cohen, Shiri, additional, Gutierrez, Alejandro, additional, Hamadani, Mehdi, additional, Hari, Parameswaran N., additional, Hartwig, John H., additional, Hayman, Suzanne R., additional, Hayward, Catherine P.M., additional, Hebbel, Robert P., additional, Heslop, Helen E., additional, Hillis, Christopher, additional, Hillyer, Christopher D., additional, Ho, Karin, additional, Hockenbery, David M., additional, Hoffman, Ronald, additional, Hogg, Kerstin E., additional, Holtan, Shernan G., additional, Horny, Hans-Peter, additional, Hsu, Yen-Michael S., additional, Hunter, Zachary R., additional, Huntington, James A., additional, Iancu-Rubin, Camelia, additional, Iqbal, Ali, additional, Isenman, David E., additional, Israels, Sara J., additional, Italiano, Joseph E., additional, Jaffe, Elaine S., additional, Jaffer, Iqbal H., additional, Jagannath, Sundar, additional, Jäger, Ulrich, additional, Jain, Nitin, additional, James, Paula, additional, Jeha, Sima, additional, Jordan, Michael B., additional, Josephson, Cassandra D., additional, Jung, Moonjung, additional, Kager, Leo, additional, Kambayashi, Taku, additional, Kanakry, Jennifer A., additional, Kantarjian, Hagop M., additional, Kaplan, Jason, additional, Karafin, Matthew S., additional, Karsan, Aly, additional, Kaufman, Randal J., additional, Kaufman, Richard M., additional, Keller, Frank G., additional, Kelly, Kara M., additional, Kessler, Craig M., additional, Key, Nigel S., additional, Keyzner, Alla, additional, Khandoga, Alexander G., additional, Khanna-Gupta, Arati, additional, Khatib-Massalha, Eman, additional, Klein, Harvey G., additional, Knoechel, Birgit, additional, Kollet, Orit, additional, Konkle, Barbara A., additional, Kontoyiannis, Dimitrios P., additional, Koreth, John, additional, Koretzky, Gary A., additional, Kotecha, Dipak, additional, Kremyanskaya, Marina, additional, Kumari, Anju, additional, Kuzel, Timothy M., additional, Küppers, Ralf, additional, Lacy, Martha Q., additional, Ladas, Elana, additional, Landier, Wendy, additional, Lapid, Kfir, additional, Lapidot, Tsvee, additional, Larson, Peter J., additional, Levi, Marcel, additional, Lewis, Russell E., additional, Liebman, Howard A., additional, Lillicrap, David, additional, Lim, Wendy, additional, Lin, Judith C., additional, Lindblad, Robert, additional, Lip, Gregory Y.H., additional, Little, Jane A., additional, Lohr, Jens G., additional, López, José A., additional, Luscinskas, Francis W., additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneet S., additional, Manches, Olivier, additional, Mandle, Robert J., additional, Mann, Kenneth G., additional, Manno, Catherine S., additional, Marcogliese, Andrea N., additional, Mariani, Guglielmo, additional, Marincola, Francesco M., additional, Mascarenhas, John, additional, Massberg, Steffen, additional, McEver, Rodger P., additional, McGrath, Emer, additional, McKinney, Matthew S., additional, Mehta, Rohtesh S., additional, Mentzer, William C., additional, Merlini, Giampaolo, additional, Merryman, Reid, additional, Michel, Marc, additional, Migliaccio, Anna Rita, additional, Miller, Jeffrey S., additional, Mims, Martha P., additional, Mondoro, Traci Heath, additional, Moorehead, Paul, additional, Muniz, Luciana R., additional, Munshi, Nikhil C., additional, Najfeld, Vesna, additional, Nayak, Lalitha, additional, Nazy, Ishac, additional, Neff, Anne T., additional, Ness, Paul M., additional, Notarangelo, Luigi D., additional, O'Brien, Sarah H., additional, O'Connor, Owen A., additional, O'Donnell, Martin, additional, Olson, Amanda, additional, Orkin, Stuart H., additional, Pai, Menaka, additional, Pai, Sung-Yun, additional, Paidas, Michael, additional, Panch, Sandhya R., additional, Pande, Reena L., additional, Papayannopoulou, Thalia, additional, Parikh, Rahul, additional, Petersdorf, Effie W., additional, Peterson, Shane E., additional, Pittaluga, Stefania, additional, Ponce, Doris M., additional, Popolo, Laura, additional, Prchal, Josef T., additional, Pui, Ching-Hon, additional, Puigserver, Pere, additional, Rak, Janusz, additional, Ramos, Carlos A., additional, Rand, Jacob H., additional, Rand, Margaret L., additional, Rao, Dinesh S., additional, Ravandi, Farhad, additional, Rawlings, David J., additional, Reddy, Pavan, additional, Reding, Mark T., additional, Reiter, Andreas, additional, Rice, Lawrence, additional, Riese, Matthew J., additional, Ritchey, Arthur Kim, additional, Roberts, David J., additional, Roman, Elizabeth, additional, Rooney, Cliona M., additional, Rosen, Steven T., additional, Rosenthal, David S., additional, Rossmann, Marlies P., additional, Rot, Antal, additional, Rowley, Scott D., additional, Rubnitz, Jeffrey E., additional, Rydz, Natalia, additional, Salama, Mohamed E., additional, Sauk, Steven, additional, Saunthararajah, Yogen, additional, Savage, William, additional, Scadden, David, additional, Schaefer, Kristen G., additional, Schiffman, Fred, additional, Schneidewend, Robert, additional, Schrier, Stanley L., additional, Schuchman, Edward H., additional, Scullion, Bridget Fowler, additional, Selvaggi, Kathy J., additional, Senoo, Keitaro, additional, Shaheen, Montaser, additional, Shaz, Beth H., additional, Shelburne, Samuel A., additional, Shpall, Elizabeth J., additional, Shurin, Susan B., additional, Siegal, Deborah, additional, Silberstein, Leslie E., additional, Silberstein, Lev, additional, Silverstein, Roy L., additional, Sloan, Steven R., additional, Smith, Franklin O., additional, Smith, James W., additional, Smith, Katy, additional, Steensma, David P., additional, Steinberg, Martin H., additional, Stock, Wendy, additional, Storry, Jill R., additional, Stramer, Susan L., additional, Strauss, Ronald G., additional, Stroncek, David F., additional, Taylor, Justin, additional, Thota, Swapna, additional, Treon, Steven P., additional, Tulpule, Anil, additional, Valdes, Roberto Ferro, additional, Valent, Peter, additional, Vedantham, Suresh, additional, Vercellotti, Gregory M., additional, Verneris, Michael R., additional, Vichinsky, Elliott P., additional, von Andrian, Ulrich H., additional, Vose, Julie M., additional, Wagner, Andrew J., additional, Wang, Ena, additional, Wang, Jia-huai, additional, Warkentin, Theodore E., additional, Wasserstein, Melissa P., additional, Webster, Ann, additional, Weisdorf, Daniel J., additional, Weitz, Jeffrey I., additional, Westhoff, Connie M., additional, Wheeler, Allison P., additional, Widick, Page, additional, Wiley, James S., additional, William, Basem M., additional, Williams, David A., additional, Wilson, Wyndham H., additional, Wolfe, Joanne, additional, Wolgast, Lucia R., additional, Wood, Deborah, additional, Wu, Jennifer, additional, Yahalom, Joachim, additional, Yee, Donald L., additional, Younes, Anas, additional, Young, Neal S., additional, and Zeller, Michelle P., additional

Published
2018
Full Text
View/download PDF

39. Primary Myelofibrosis

Author

Mascarenhas, John, primary, Najfeld, Vesna, additional, Kremyanskaya, Marina, additional, Keyzner, Alla, additional, Salama, Mohamed E., additional, and Hoffman, Ronald, additional

Published
2018
Full Text
View/download PDF

40. Poster: MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis-JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib-Preliminary Data From the MANIFEST Study

Author

Mascarenhas, John, primary, Kremyanskaya, Marina, additional, Patriarca, Andrea, additional, Harrison, Claire, additional, Bose, Prithviraj, additional, Rampal, Raajit K, additional, Palandri, Francesca, additional, Devos, Timothy, additional, Passamonti, Francesco, additional, Hobbs, Gabriela, additional, Talpaz, Moshe, additional, Vannucchi, Alessandro, additional, Kiladjian, Jean-Jacques, additional, Verstovsek, Srdan, additional, Hoffman, Ron, additional, Salama, Mohamed E, additional, Chen, Dong, additional, Taverna, Pietro, additional, Chang, Alex, additional, Colak, Gozde, additional, Klein, Sandra, additional, and Gupta, Vikas, additional

Published
2022
Full Text
View/download PDF

42. The future of computational pathology: expectations regarding the anticipated role of artificial intelligence in pathology by 2030

Author

Berbís, M Alvaro, primary, McClintock, David S., additional, Bychkov, Andrey, additional, Cheng, Jerome Y, additional, Delahunt, Brett, additional, Egevad, Lars, additional, Eloy, Catarina, additional, Farris, Alton B, additional, Fraggetta, Filippo, additional, García del Moral, Raimundo, additional, Hartman, Douglas J., additional, Herrmann, Markus D, additional, Hollemans, Eva, additional, Iczkowski, Kenneth A, additional, Karsan, Aly, additional, Kriegsmann, Mark, additional, Lennerz, Jochen K, additional, Pantanowitz, Liron, additional, Salama, Mohamed E., additional, Sinard, John, additional, Tuthill, Mark, additional, Van der Laak, Jeroen, additional, Williams, Bethany, additional, Casado-Sánchez, César, additional, Sánchez-Turrión, Víctor, additional, Luna, Antonio, additional, Aneiros-Fernández, José, additional, and Shen, Jeanne, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results